ISSCA Hosting Two Upcoming Stem Cells Courses in Miami
The courses will target physicians based in the Americas, providing them with critical stem cells education and tools needed to implement protocols in their own practices
The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, is hosting two upcoming courses in Miami. The courses will inform physicians on a range of topics about the latest stem cells protocols and how they can be incorporated into physicians’ own practices.
In continuing its commitment to help alleviate human suffering through expanding physician access to today’s cutting-edge stem cells technologies, the ISSCA is bringing its globally renowned courses to Miami, offering physicians two opportunities to participate. The course offered on November 1-2 is sold out, but seats still remain for the November 29-30 session for physicians looking to incorporate stem cells treatment protocols into their practices.
Doctors attending the Miami courses will learn about the latest trends and breakthroughs in in-office stem cells protocols. The ISSCA has also added a new topic into the Miami sessions: previously, the course covered autologous cell therapy, but in this newest course iteration, speakers will discuss how to add heterologous cell therapy into medical practices. In this training, physicians will learn about treatment protocols utilizing stem cells derived from neonatal tissue, such as cord blood, exosomes, and amniotic liquid. Attendees will learn both how these products are obtained as well as their most common clinical applications.
For those interested in learning more about the ISSCA’s upcoming courses in Miami or to register, visit https://www.stemcelltraining.net/hands-on-course/
“The ISSCA is pleased to bring our highly lauded courses on stem cells protocols to physicians in the Miami area and beyond,” said Benito Novas, ISSCA VP of Public Relations. “Our goal is to help physicians better treat their patients suffering from degenerative diseases by giving them the tools and education they need to implement these highly effective protocols in their own practices. Like all of our educational sessions, our Miami courses have been met with a great response, proving the growing interest in and efficacy of stem cells treatments.”
To learn more about all of the ISSCA’s latest news and innovations, visit http://www.stemcellsgroup.com/
- Published in Press Releases
Buenos Aires Stem Cells Symposium Draws Hundreds of Physicians from across the Globe
The ISSCA sponsored symposium is in its sixth year, sharing recent advancements in stem cells therapies with physicians looking to implement them into their own practices
The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, recently hosted a symposium in Buenos Aires, aimed at physicians looking to incorporate regenerative medicine into their practices.
The 6th Simposio Mundial sobre Medicina Regenerativa y Terapias Celulares was held in Buenos Aires, Argentina on October 12-13, with 300 physicians in attendance. The event has become a premier global event in the world of regenerative medicine, attracting a growing number of returning physicians each year.
The 6th annual event featured 13 expert speakers from five countries, including Argentina, Chile, Colombia, Bolivia, Cuba, and the US. The panel of speakers included practitioners within the regenerative medicine field as well as scientists currently working on developing new stem cells protocols and allogeneic compounds. Throughout the weekend, physicians attended lectures providing information on how stem cell therapies can help patients suffering from degenerative diseases.
The event was sponsored by the City of Buenos Aires, which was pleased to host the event in the city and has invited the group back next year to host its 7th annual event.
All of the symposium’s lectures will be posted to ISSCA’s YouTube channel, with free viewing access to the public. Those interested in viewing the symposium’s lectures can visit
https://www.youtube.com/user/StemCellsGroup/videos.
“For six years now, ISSCA has proudly sponsored the Simposio Mundial sobre Medicina Regenerativa y Terapias Celulares, bringing physicians from across the globe together to learn about the newest advancements in stem cells therapies,” said Benito Novas, ISSCA VP of Public Relations. “This year’s event was a great success, and we would like to thank all of the attending physicians, our panel of expert speakers, and the City of Buenos Aires for graciously hosting us.”
To learn more about all of the ISSCA’s latest news and innovations, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
ISSCA Set to Sponsor Stem Cells Certification Course in Belgium
The certification will target physicians in the Middle East and Europe, providing them with critical education to implement stem cells treatments in their own practices
The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, is continuing its mission to become a world leader in regenerative medicine education by adding a new Stem Cells Certification course to its portfolio.
Over the past few months, ISSCA has expanded its reach both through offering new certification courses and by opening new stem cells treatment centers across the globe. The group’s latest Stem Cells Certification course will be offered in Brussels, Belgium, giving physicians in both Europe and the Middle East who have an interest in incorporating regenerative medicine into their practices easier access to critical educational opportunities led by some of the world’s leading experts in the field.
The Brussels course is a collaboration between Belgium-based physician Dr. Samy Joheir, ISSCA Europe, and ISSCA. Participants in the upcoming course are expected to come from the Middle East, specifically from Pakistan and India. The participating physicians are eager to add cell therapies to their practices to better serve patients who are suffering from degenerative conditions.
Physicians attending the certification will learn easy-to-implement protocols that will allow them to harvest and reintegrate stem cells in their own medical offices. The practices shared in the certification will focus on utilization of two different resources: fat tissue and bone marrow tissue.
Physicians interested in learning more about any of ISSCA’s Stem Cells Certification courses are invited to visit https://www.stemcelltraining.net/belgium-hands-on-course/
“The ISSCA is continuing to make good on its mission to alleviate human suffering due to degenerative diseases by providing more physicians across the globe access to critical stem cells training courses,” said Benito Novas, ISSCA VP of Public Relations. “The upcoming course in Belgium will give physicians across Europe and the Middle East critical opportunities to obtain the education needed to utilize today’s cutting-edge stem cells therapies and give them the tools they need to incorporate these life-changing protocols into their own practices.”
To learn more about all of the ISSCA’s latest news and innovations, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Cellgenic Set to Open New Stem Cells Center in Belgium through Partnership with Churchill Aesthetic Center
The subsidiary of the Global Stem Cells Group seeks to meet the growing demand for patients seeking stem cells treatments across the globe.
MIAMI LAKES, Florida— Cellgenic, a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an agreement that will bring regenerative medical treatments to more patients across Europe with the opening of a new stem cells treatment center in Belgium.
The agreement, signed between the GSCG and Dr. Samy Joheir, owner of Churchill Aesthetic Center (https://www.churchill-aesthetic-center.be/), expands the GSCG’s mission of expanding access to regenerative medicine globally. The agreement opens the center’s doors to patients seeking stem cells treatment options and to physicians across Europe and the Middle East seeking educational opportunities regarding how to incorporate regenerative medicine into their practices. The center is located at 141 Winston Churchill Avenue, B-1180 in Brussels.
The Brussels center will also serve as the GSCG’s head offices and will help the group better serve patients and doctors across Europe and the Middle East.
To new center will officially open on September 30, 2019. In conjunction with the center’s opening, the GSCG and Dr. Joheir will welcome three patients from the Middle East seeking treatments offered by the center. These patients were previously treated in the US prior to the institution of stricter FDA stem cells regulations. The Belgium center will provide these patients with treatment options closer to home, alleviating emotional, financial, and physical stressors in receiving treatment, similar to the group’s current facilities in Cancun that provide critical stem cells treatment to patients traveling from the US.
With the opening of the center, the GSCG also aims to provide more accessible educational facilities and options for physicians in the region looking to receive training in regenerative medicine. The training is in alignment with the services currently offered at the GSCG’s other facilities, such as those located in Cancun for physicians across the Americas.
Over the past few years, the GSCG has sought to achieve its mission in helping to alleviate human suffering by opening stem cells centers across the globe to meet growing patient demands. All of the group’s centers are all currently located outside of the US due to current FDA regulations restricting regenerative medicine products and protocols.
“The Global Stem Cells Group is pleased to be able to reach more patients seeking relief through regenerative medicine with the opening of our Belgian center,” said Benito Novas, CEO of the Global Stem Cells Group. “This expansion will help alleviate travel and financial barriers some European and Middle Eastern patients face in receiving the care they need, now providing them access to a facility closer to home. We are committed to opening up additional treatment centers for both physicians and patients across the globe who may be limited by their local regulations in accessing critical stem cells therapies. Through our facilities, patients looking for relief from regenerative diseases will receive top-notch care in state-of-the-art facilities.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Global Stem Cells Group Set to Conduct Clinical Trials in Miami
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.
The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.
The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.
“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”
To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Lans Holdings Secures Extension to Complete Acquisition of Global Stem Cells Group
MIAMI, FL, Sept. 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG).
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
- Published in Press Releases
ISSCA Set to Welcome 13 Speakers at Upcoming Symposium in Miami
The regenerative medicine symposium will be held on the University of Miami campus on October 24, 2019.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA) has announced its lineup of speakers for its upcoming Regenerative Medicine Symposium. The symposium will be held on the University of Miami campus in the Donna E. Shalala Student Center on October 24, 2019 and features an impressive lineup of global authorities in regenerative medicine.
ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. This year’s symposium hosted on the University of Miami campus will feature industry experts from seven countries, including Spain, Argentina, Bolivia, Colombia, Ecuador, Mexico, and the US. Some notable speakers include the following:
- Dra. Silvina Pastrana from Argentina, who serves as the Medical Director of the Stem Cells Center Buenos Aires. Dra. Pastrana will discuss her experiences in treating patients who suffer from osteoarthritis conditions.
- Dr. Pedro Sanchez hails from Colombia and is a highly regarded regenerative medicine and orthopedic specialist. He currently practices in Bogota where he offers stem cells treatments for people who suffer from orthopedic conditions.
- Dr. Miguel Guillermo Garbe of Spain serves as the president of the country’s Regenerative Medicine Association. He currently leads a seminal investigation on how to increase cardiological function in patients who have suffered from strokes.
- Dr. Roberto Blum from Ecuador has worked in the stem cells field for over 10 years and will share his industry experience with attendees.
- Dr. Victor Pereyra, an Argentinian neurosurgeon, will lecture on how ozone therapy and stem cells could help patients suffering from spinal injuries.
“The symposium will provide an informative day where physicians can learn from global leaders in the stem cells industry with the hopes of bringing new knowledge and treatment options back to their practices for their patients suffering from degenerative diseases.”
To learn more about the ISSCA and its Miami symposium, visit
http://www.stemcellsgroup.com/.
.
- Published in Press Releases
GSCG Meets Demands of Patients Seeking Stem Cells Treatment with New Facilities
The group’s new permanent office in Cancun will help streamline the patient experience by providing holistic support throughout the treatment process.
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) today announced that it will be opening a permanent office in Cancun, Mexico. The decision to expand its corporate presence into Cancun was based on the rising demand for patients seeking stem cells treatments at the group’s facilities already established in Cancun. The GSCG maintains two regenerative medicine operations in Cancun, which include medical facilities and a stem cells laboratory.
GSCG’s Cancun facilities provide state-of-the art options for patients seeking stem cells treatments that are currently not available in the US. While these protocols and products are currently unavailable within the US’s borders due to regulations, the Cancun center has still adopted the FDA’s frameworks for safe and effective regenerative medicine products and therapies. Guided by these protocols, physicians at the center deliver safe and effective stem cells therapies and products that can help patients suffering from degenerative diseases recover more quickly than with traditional treatment protocols.
With the establishment of a permanent office presence in Cancun, the GSCG seeks to provide a seamless holistic experience for patients seeking treatment at its facilities. With its office located near its medical center and laboratory, the GSCG team can more closely monitor the treatment process from the time the patient arrives at the Cancun airport to the time their treatment is complete and they return to the US.
“The Global Stem Cells Group is pleased to establish a permanent presence in Cancun with the opening of this new office location,” said Benito Novas, CEO of the Global Stem Cells Group. “By expanding our presence, we will be able to open up additional treatment opportunities for physicians in the US who may be limited by FDA regulations in ensuring their patients receive the critical stem cells therapies they need. US patients looking for relief from regenerative diseases are welcome at our Cancun center and will appreciate our state-of-the art facilities and top-notch care.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
.
- Published in Press Releases
Benito Novas of Aesthetica Marketing Group Set as Keynote for Chilean Aesthetics Congress
The keynote will highlight trends in social media marketing for physicians working in aesthetics
MIAMI LAKES, Florida—Benito Novas, CEO of Aesthetica Marketing Group (AMG), has been selected to serve as the keynote speaker at the upcoming Congreso del la Sociedad Chilena de Medicina y Estética. AMG, which is sponsoring the Chilean congress, is an American company focused on providing doctors working in the aesthetics medical industry practical solutions for their marketing challenges. The congress will be held on August 22-24, 2019 at the Hotel InterContinental Santiago in Santiago, Chile.
The annual event is the group’s main event, attracting physicians in the aesthetics medical industry across Chile and beyond. Novas’ keynote lecture will highlight current trends and best practices in social media and how physicians working in the aesthetics industry can better leverage social media in increasing the success of their practices.
During the congress, AMG will also launch two new courses focused on the aesthetics market, Pellet Therapy Certification and an IV/Chelation course.
The Pellet Therapy Certification course will provide practitioners with comprehensive clinical knowledge of this therapy option—one that is gaining rapid traction and recognition globally. Facilitators will present scientific reviews, case studies, and procedural training during the workshop. Attendees will be provided an in-depth introduction to pellet therapy, supported by reviews of clinical evidence on the need for customized dosing, in addition to assessing pellet dosing protocols for male and female patients. Pellet sterility, equipment, and what to look for in a compounding pharmacy will also be discussed.
AMG’s IV/Chelation course has been redesigned and now includes the most recent practices and protocols in intravenous nutritional therapies, in addition to chelation therapy in regard to its uses in lead toxicity and other heavy metals. Lecturers will not only cover the fundamentals of IV therapy and expand on the use of vitamins, minerals, amino acids, and other unique parenteral compounds but also review various aspects of integrating IV therapy into practice, as well as implementation strategies. Faculty presenters additionally will discuss potential application of the therapy in cancer treatment protocols, thus giving attendees the unique opportunity to learn about the most cutting-edge uses of IV therapy as a treatment method. At the conclusion of the course, clinicians will have a thorough understanding of how to perform IV therapy in both theory and practice.
To learn more about the upcoming Congreso del la Sociedad Chilena de Medicina y Estética or to register, visit https://sochimce.cl/congreso/. To learn more about Aesthetica Marketing Group, visit https://esteticamarketing.com/.
.
- Published in Press Releases
Benito Novas to Serve as Keynote Speaker at Mexican Aesthetic Gynecology Congress
The Global Stem Cells CEO will give two additional lectures on marketing and future outlooks for the stem cells industry as well as lead a magistral class for attendees
MIAMI LAKES, Florida—Benito Novas has been invited as a keynote speaker at an upcoming medical congress hosted by the Mexican Board of Aesthetic Gynecology. The group’s fourth congress, the 4to Congreso Internacional de Ginecología Lasar y Funcional, will be held on September 25-28, 2019 at the Holiday Inn hotel in Boca del Rio in Veracruz, Mexico.
Novas, is the Vice President of Public Relations of the International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. In addition to his keynote speech, Novas will also lecture on two additional topics during the congress as well as lead a magistral class for conference attendees.
Benito Novas is a highly sought-after speaker in the world of stem cell advancements, having served as a successful business owner in the industry with his holding the Global Stem Cells Group. Thanks to Novas’ and his team’s efforts, access to regenerative medicine has expanded exponentially across the globe. Additionally, Novas is a well-regarded marketing professional who has created a successful marketing model for private medical organizations to expand and grow their industry recognition.
Congress attendees will have the opportunity to hear Novas’ talks on the current and future state of stem cells as well as the importance of digital marketing in the medical field. In his lecture on current and future outlooks for stem cells advancement, Novas will share information about current stem cells clinical trials and growing expectations in the industry as well as how FDA policies can influence markets not only in the US but also beyond.
In his lecture on digital marketing, Novas will address why doctors must utilize digital marketing strategies to grow a successful practice. He will look at current trends in how people meet each other and network in today’s increasingly digital world and how social medial plays a role in today’s networking. He will additionally provide strategic tips to attendees on how to capitalize on social media trends to grow practice influence. Some of the tools Novas will discuss include Google Ads and Facebook Ads, as well as what type of content to post to generate engagement with prospective customers and clients.
Novas will also conduct a magistral class following the congress for professionals interested in learning more about digital marketing. During the course, Novas will discuss how practitioners can implement the latest marketing techniques into their practices, including how to create a powerhouse digital marketing team by using platforms such as Fiverr, Upwork, and others.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
.
- Published in Press Releases
